Homburger advised BioVersys on the extension of its Series C fundraising round

On January 5, 2023, BioVersys announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 million. The Swiss pharma company represents the first European-based investment of the AMR Action Fund. The funds will go towards further trials of the pharmaceutical company’s assets.

BioVersys is a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is a Venture Kick winner as well as a Venture Leaders alum. It ranked among the TOP 100 Swiss Startups from 2011 to 2013.

Homburger has advised BioVersys in this transaction. The legal team comprised partner Dieter Gericke (pictured left) and associate Thierry Burckhardt (pictured right; both Corporate / M&A).

Homburger advised BioVersys on the extension of its Series C fundraising round



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram